📊 ADXN Key Takeaways
Is Addex Therapeutics Ltd. (ADXN) a Good Investment?
Insufficient financial data available for meaningful fundamental analysis. Unable to assess profitability, financial health, or operational trends due to lack of reported metrics across income statement, balance sheet, and cash flow statements.
Addex Therapeutics remains a development-stage biotech with minimal recurring revenue, persistent operating losses, and deteriorating cash resources despite some cost discipline. The balance sheet carries little traditional debt and still shows positive equity, but the core fundamental issue is financing risk: management disclosed substantial doubt about continuing as a going concern without additional capital or partnership funding.
Why Buy Addex Therapeutics Ltd. Stock? ADXN Key Strengths
- Listed on Nasdaq indicating regulatory compliance and market access
- Low financial leverage, with no material traditional debt burden and liabilities remaining modest relative to assets
- Operating cost base improved versus the prior-year interim period, with first-half 2025 operating loss lower than first-half 2024
- Positive reported equity and ownership in Neurosterix provide some balance-sheet support beyond cash alone
ADXN Stock Risks: Addex Therapeutics Ltd. Investment Risks
- Complete absence of revenue and profitability data prevents assessment of business viability
- No balance sheet metrics available to evaluate financial stability or liquidity
- Inability to determine if company is pre-revenue, in development stage, or experiencing reporting issues
- No cash flow data to assess burn rate or operational sustainability
- Zero insider activity in last 90 days suggests lack of insider confidence or dormancy
- Revenue quality is weak and inconsistent, with 2024 revenue falling sharply and first-half 2025 revenue remaining negligible
- Cash fell to about CHF 2.3 million by June 30, 2025 while operations continued to consume cash, leaving a short funding runway
- Management stated that substantial doubt exists about the company’s ability to continue as a going concern without new financing or collaboration inflows
Key Metrics to Watch
- Revenue generation and gross margins once available
- Operating cash flow and cash position relative to burn rate
- Pipeline progress and clinical trial results for therapeutic candidates
- Cash and cash equivalents relative to quarterly operating cash burn
- Collaboration/licensing revenue and milestone inflows sufficient to offset continuing R&D losses
Addex Therapeutics Ltd. (ADXN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ADXN Profit Margin, ROE & Profitability Analysis
ADXN vs Healthcare Sector: How Addex Therapeutics Ltd. Compares
How Addex Therapeutics Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Addex Therapeutics Ltd. Stock Overvalued? ADXN Valuation Analysis 2026
Based on fundamental analysis, Addex Therapeutics Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Addex Therapeutics Ltd. Balance Sheet: ADXN Debt, Cash & Liquidity
ADXN Revenue Growth, EPS Growth & YoY Performance
ADXN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Addex Therapeutics Ltd. (CIK: 0001574232)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ADXN
What is the AI rating for ADXN?
Addex Therapeutics Ltd. (ADXN) has a Combined AI Rating of SELL from Claude (HOLD) and ChatGPT (STRONG SELL) with 52% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ADXN's key strengths?
Claude: Listed on Nasdaq indicating regulatory compliance and market access. ChatGPT: Low financial leverage, with no material traditional debt burden and liabilities remaining modest relative to assets. Operating cost base improved versus the prior-year interim period, with first-half 2025 operating loss lower than first-half 2024.
What are the risks of investing in ADXN?
Claude: Complete absence of revenue and profitability data prevents assessment of business viability. No balance sheet metrics available to evaluate financial stability or liquidity. ChatGPT: Revenue quality is weak and inconsistent, with 2024 revenue falling sharply and first-half 2025 revenue remaining negligible. Cash fell to about CHF 2.3 million by June 30, 2025 while operations continued to consume cash, leaving a short funding runway.
What is ADXN's revenue and growth?
Addex Therapeutics Ltd. reported revenue of N/A.
Does ADXN pay dividends?
Addex Therapeutics Ltd. does not currently pay dividends.
Where can I find ADXN SEC filings?
Official SEC filings for Addex Therapeutics Ltd. (CIK: 0001574232) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ADXN's EPS?
Addex Therapeutics Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ADXN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Addex Therapeutics Ltd. has a SELL rating with 52% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ADXN stock overvalued or undervalued?
Valuation metrics for ADXN: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ADXN stock in 2026?
Our dual AI analysis gives Addex Therapeutics Ltd. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ADXN's free cash flow?
Addex Therapeutics Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.
How does ADXN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).